- Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Travere Therapeutics to Present at National Kidney Foundation Spring Clinical Meetings and the 61st European Renal Association Congress
- Travere Therapeutics to Present at Upcoming Investor Conferences
- Travere Therapeutics Reports First Quarter 2024 Financial Results
- Travere Therapeutics to Report First Quarter 2024 Financial Results
- Travere Therapeutics and CSL Vifor Announce European Commission Approves FILSPARI® (sparsentan) for the treatment of IgA Nephropathy
- Travere Therapeutics to Present Abstracts at the Society for Inherited Metabolic Disorders and Genetic Metabolic Dieticians International
- Travere Therapeutics to Present Abstracts on FILSPARI® (sparsentan) in IgA Nephropathy at World Congress of Nephrology and the American Nephrology Nurses Association
- Travere Therapeutics Submits Supplemental New Drug Application to the U.S. Food and Drug Administration Seeking Full Approval of FILSPARI® (sparsentan) for the Treatment of IgA Nephropathy (IgAN)
- Travere Therapeutics and CSL Vifor Announce Sparsentan Receives Positive CHMP Opinion for the Treatment of IgA Nephropathy
More ▼
Key statistics
As of last trade, Travere Therapeutics Inc (TVTX:NMQ) traded at 6.28, 22.66% above the 52 week low of 5.12 set on Apr 25, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 6.56 |
---|---|
High | 6.56 |
Low | 6.26 |
Bid | 6.27 |
Offer | 6.28 |
Previous close | 6.56 |
Average volume | 1.03m |
---|---|
Shares outstanding | 76.13m |
Free float | 75.56m |
P/E (TTM) | -- |
Market cap | 499.41m USD |
EPS (TTM) | -5.32 USD |
Data delayed at least 15 minutes, as of May 23 2024 19:09 BST.
More ▼